FMP

FMP

Enter

KURA - Kura Oncology, Inc.

Financial Summary of Kura Oncology, Inc.(KURA), Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatmen

photo-url-https://financialmodelingprep.com/image-stock/KURA.png

Kura Oncology, Inc.

KURA

NASDAQ

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

21.17 USD

-0.26 (-1.23%)

About

ceo

Dr. Troy Edward Wilson J.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://kuraoncology.com

exchange

NASDAQ

Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a ...

CIK

0001422143

ISIN

US50127T1097

CUSIP

50127T109

Address

12730 High Bluff Drive

Phone

858 500 8800

Country

US

Employee

142

IPO Date

Sep 16, 2015

Summary

CIK

0001422143

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

50127T109

ISIN

US50127T1097

Country

US

Price

21.17

Beta

0.89

Volume Avg.

864.31k

Market Cap

1.61B

Shares

-

52-Week

7.41-24.17

DCF

0.27

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-9.76

P/B

-

Website

https://kuraoncology.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest KURA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep